BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis

SIMPLE SUMMARY: To date, one of the reference therapies for the treatment of mutated BRAF metastatic melanoma is based on the combination of BRAF and MEK inhibitors. Although many trials have compared BRAF and MEK inhibitor combination therapies, there is no evidence of superiority in the use of one...

Descripción completa

Detalles Bibliográficos
Autores principales: Garutti, Mattia, Bergnach, Melissa, Polesel, Jerry, Palmero, Lorenza, Pizzichetta, Maria Antonietta, Puglisi, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818023/
https://www.ncbi.nlm.nih.gov/pubmed/36612138
http://dx.doi.org/10.3390/cancers15010141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818023/
https://www.ncbi.nlm.nih.gov/pubmed/36612138
http://dx.doi.org/10.3390/cancers15010141

Ejemplares similares